BTK PROTAC Degrades Kinase via E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BTK inhibitors are not potent enough and lack alternative strategies for degrading Bruton's tyrosine kinase (BTK), which is crucial for treating autoimmune and inflammatory diseases, as well as cancer.
Innovation Solution
Development of novel bifunctional PROTAC compounds that conjugate BTK inhibitor moieties with E3 ligase ligands to recruit targeted proteins to E3 ubiquitin ligase for degradation, specifically using 3,5-disubstituted-1H-pyrazolo[3,4-b]pyridine as a BTK inhibitor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional BTK inhibitors are used, then BTK activity is inhibited, but the inhibition potency is insufficient and alternative degradation strategies are lacking
Solution Approach 1:
The patent combines a BTK inhibitor moiety with an E3 ligase ligand moiety into a single bifunctional PROTAC compound. This merging allows the molecule to simultaneously inhibit BTK and recruit E3 ubiquitin ligase for targeted degradation, thereby enhancing both inhibition potency and providing a novel degradation strategy beyond conventional inhibition approaches.
Solution Approach 2:
The bifunctional PROTAC compound performs multiple functions: it acts as a BTK inhibitor, an E3 ligase recruiter, and a proteasome-mediated degradation inducer. This multi-functionality addresses the limitation of conventional single-function BTK inhibitors by providing both inhibition and degradation capabilities within one molecule, enhancing therapeutic versatility.
2Reliability
If bifunctional PROTAC compounds are developed to enhance BTK degradation, then degradation potency is improved, but molecular complexity increases
Solution Approach 1:
The PROTAC compound is segmented into distinct functional moieties: a BTK inhibitor portion and an E3 ligase ligand portion, connected by a linker. This segmentation allows each component to perform its specific function while maintaining overall molecular functionality, managing complexity through modular design.
Solution Approach 2:
The linker acts as an intermediary component connecting the BTK inhibitor moiety and the E3 ligase ligand moiety. This intermediary structure enables proper spatial arrangement and facilitates simultaneous binding to both BTK and E3 ligase, resolving the complexity challenge by providing a structured bridge between functional elements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel PROTAC compounds effectively degrade BTK, offering a potent and alternative strategy for treating autoimmune and inflammatory diseases, as well as cancer, by leveraging the ubiquitin-proteasome pathway for protein degradation.
Implementation Method 1
Ubiquitin, which is highly conserved in eukaryotic cells, is a modifier molecule, composed of 76 amino acids, that covalently binds to and labels target substrates via a cascade of enzymatic reactions involving E1, E2, and E3 enzymes.
Implementation Method 2
Subsequently, the modified substrate is recognized by the 26S proteasome complex for ubiquitination-mediated degradation.
Data Source
AI summary
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.